Open AccessUpdate on systemic treatment in early triple negative breast cancer
Author(s) -
M. Nunez Abad,
Silvia CalabuigFariñas,
M. Lobo de Mena,
María José Godes Sanz de Bremond,
C. García González,
Susana TorresMartínez,
José Ángel García,
Vega Iranzo,
Carlos Camps Herrero
Publication year - 2021
Publication title -
therapeutic advances in medical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 49
eISSN - 1758-8359
pISSN - 1758-8340
DOI - 10.1177/1758835920986749
Subject(s) - medicine , triple negative breast cancer , breast cancer , systemic therapy , oncology , chemotherapy , triple negative , disease , cancer , pathological
Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom